Cytek Biosciences Form 4: 67,782 Equity Awards to Director Jack Ball

Rhea-AI Filing Summary

Cytek Biosciences, Inc. (CTKB) – Form 4 filing dated 06/20/2025

The filing discloses new equity awards granted to director Jack Ball on 06/18/2025. Two separate instruments were reported:

• Restricted Stock Units (RSUs): 43,973 units, each convertible into one common share. 100 % of the award vests on the earlier of 18 Jun 2026 or the company’s 2026 annual meeting (if held in June 2026). Upon vesting, Ball will receive an equivalent number of common shares.
• Non-qualified Stock Option: Right to purchase 23,809 common shares at an exercise price of $3.07 per share. The option follows the same vesting schedule as the RSUs and carries an expiration date of 18 Jun 2035.

Following these grants, Ball’s directly held derivative positions now include the 43,973 RSUs and 23,809 options; no indirect ownership was reported. The filing does not indicate any sale or disposition of existing shares, and no Rule 10b5-1 trading plan box was checked.

The awards represent routine director compensation and do not provide quantitative information on Cytek’s overall share count, dilution impact, or financial performance. No earnings data, cash payments, or other material corporate actions accompany the disclosure.

Insights

Financial Analyst

TL;DR: Routine director equity award; no immediate cash flow impact, modest potential dilution.

The filing simply documents standard board compensation: 43,973 RSUs and 23,809 options at $3.07 to Director Jack Ball. Vesting is one-year cliff, aligning incentives through 2026. Because no shares were sold, the transaction is non-cash and has no short-term P&L effect. Potential dilution is minimal given Cytek’s multi-million-share base, but investors should be aware that up to 67,782 new shares could enter the float after vesting/exercise if Ball holds and later sells. Overall, the disclosure is administratively important yet financially neutral.

Corporate Governance Expert

TL;DR: Equity package aligns director with shareholders; governance standard, limited materiality.

Granting RSUs and at-the-money options with a one-year cliff is common practice for Nasdaq-listed med-tech boards. Cytek ties vesting to either a fixed date or the 2026 AGM, encouraging director continuity through the next proxy cycle. There is no indication of accelerated vesting, performance hurdles, or employment-related clauses that would raise governance red flags. Absence of a 10b5-1 plan box suggests discretionary holding rather than pre-programmed sales. From a governance lens, this is transparent and routine, carrying neutral investor impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ball Jack

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BLVD.

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/18/2025		A		43,973		(2)	(2)	Common Stock	43,973	$0	43,973	D
Director Stock Option (right to buy)	$3.07	06/18/2025		A		23,809		(3)	06/18/2035	Common Stock	23,809	$0	23,809	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

3. 100% of the shares subject to the option shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

	/s/ Valerie Barnett, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Cytek Biosciences (CTKB) shares did Director Jack Ball receive in the latest Form 4?

The filing reports 43,973 RSUs plus 23,809 stock options, totaling 67,782 potential common shares.

What is the exercise price of Jack Ball’s new CTKB stock options?

Each option carries an exercise price of $3.07 per common share.

When will the RSUs and options granted to Jack Ball vest?

Both awards vest 100 % on the earlier of 18 Jun 2026 or the 2026 annual shareholder meeting (if held in June 2026).

Does the Form 4 indicate that Jack Ball sold any CTKB shares?

No. The filing lists only acquisitions (code "A"); there are no dispositions or sales reported.

Is there a Rule 10b5-1 trading plan associated with this transaction?

The checkbox for a Rule 10b5-1 plan was not marked, indicating the awards were not made under such a plan.